The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESH MDS 2021 | Key clinical trials in high-risk and low-risk MDS
Uwe Platzbecker, MD, University of Leipzig, Leipzig, Germany, discusses key clinical trials in the field of myelodysplastic syndromes (MDS) at ESH MDS 2021. In low-risk MDS, Prof. Platzbecker highlights a study evaluating imetelstat (NCT02598661) and the COMMANDS study (NCT03682536) comparing luspatercept versus the standard of care (SOC), epoetin alfa (EPO), in low-risk MDS patients. In high-risk MDS, Prof. Platzbecker discusses trials combining novel agents with SOC hypomethylating agents (HMA) with venetoclax, magrolimab or pevonedistat, and the Phase II STIMULUS-MDS1 (NCT03946670) and Phase III STIMULUS-MDS2 studies (NCT04266301) investigating sabatolimab for high-risk MDS. This interview took place during the 2021 European School of Hematology (ESH) 7th Translational Research E-Conference on Myelodysplastic Syndromes.
